Lymphoma | Topics

Epcoritamab Monotherapy Demonstrates Promising Early Findings for Patients With R/R B-Cell non-Hodgkin Lymphoma
September 10, 2021

Epcoritamab monotherapy yielded positive results in patients with relapsed/refractory B-cell non-Hodgkin lymphoma and should be studied further, according to investigators.

John Pagel, MD, PhD, Discusses Key Takeaways of a Trial Examining Zanubrutinib Plus Zandelisib in B-Cell Malignancies
September 07, 2021

The combination of zanubrutinib and zandelisib for the treatment of B-cell malignancies may offer patients the opportunity to receive therapy that is not based around chemotherapy.

John Pagel, MD, PhD, Discusses Dosing Regimens and Toxicity Associated With Zanubrutinib and Zandelisib
September 04, 2021

Zanubrutinib and zandelisib combination appears to be a well-tolerated regimen for the treatment of B-cell malignancies, according to early study results.